| Market Cap | $123.73M-60.3% |
| Revenue (ttm) | $2.40M |
| Net Income | -$94.76M |
| EPS | -$0.45 |
| Shares Out | 277.80M |
| PE Ratio | n/a |
| Forward PE | -1.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,771,034 |
| Open | $0.51 |
| Previous Close | $0.54 |
| Day's Range | $0.44 - $0.52 |
| 52-Week Range | $0.34 - $1.52 |
| Beta | 2.68 |
| Analysts | Buy |
| Price Target | $1.64(+268.58%) |
| Earnings Date | Nov 10, 2026 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Humacyte, Inc. Stock Analysis — InsiderScore
Humacyte, Inc. scored higher than 0% of companies evaluated by InsiderBuying, and ranked 107th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Humacyte, Inc. bought $5.6K of stock across 1 purchase in the last 90 days, the largest of them $5.6K.
The average purchase added about 25% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating HUMA in the last 3 months, one vote each. Issuer-paid research is not counted.
$HUMA stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of HUMA by members of U.S. Congress
| Tommy TubervilleSenate / R | Purchase$1.00K – $15.00K | Mar 21, 2024 |
| Tommy TubervilleSenate / R | Purchase$15.00K – $50.00K | Mar 21, 2024 |
Recently reported changes in HUMA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HUMA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HUMA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New HUMA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HUMA from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from HUMA’s recent data — informational, not investment advice
What’s Behind the Score
News check: FDA regulatory progress, 151% revenue surge in key product, expanding clinical evidence, and strong commercial adoption drive notably positive coverage.
Recent Insider Activity
Insider Score Trend Over Time
-17.5 since Sep 23Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SPXZ | Morgan Creek - Exos SPAC Originated ETF | 1.50% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.08% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.01% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
